Table 3.
Overall survival and progression‐free survival according to the VEGFR2 rs1870377T>A genotype
| Polymorphism/genotype | No. of patients | % | Overall survival | Progression‐free survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of deaths | % | 3‐year OS | HR | 95% CI | P* | No. of events | % | 3‐year PFS | HR | 95% CI | P* | |||
| VEGFR2 rs1870377 | ||||||||||||||
| TT | 169 | 35.5 | 61 | 36.1 | 63.7 | 1 | 0.004 | 69 | 40.8 | 56.7 | 1 | 0.010 | ||
| TA | 219 | 46.0 | 58 | 26.5 | 73.4 | 0.656 | 0.458–0.940 | 0.022 | 67 | 30.6 | 68.0 | 0.676 | 0.483–0.947 | 0.023 |
| AA | 88 | 18.5 | 15 | 17.0 | 81.6 | 0.427 | 0.243–0.751 | 0.003 | 21 | 23.9 | 76.7 | 0.519 | 0.318–0.846 | 0.009 |
| TA + AA | 307 | 64.5 | 73 | 23.8 | 75.7 | 0.591 | 0.420–0.830 | 0.002 | 88 | 28.7 | 70.5 | 0.631 | 0.460–0.865 | 0.004 |
*P‐values < 0.025 were statistically significant for Bonferroni correction for multiple testing. OS, overall survival; PFS, progression‐free survival.